{"type":"trials","record":{"id":41835,"source_id":"clinicaltrials-gov","external_id":"NCT05972473","title":"A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD","brief_summary":"The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.","overall_status":"Active Not Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrollment":600,"countries":["China"],"start_date":"2023-09-21","completion_date":"2027-04-30","last_update_date":"2025-03-13","source_url":"https://clinicaltrials.gov/study/NCT05972473","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Aflibercept","organization":"Innovent Biologics (Suzhou) Co. Ltd.","interventions":["Aflibercept Ophthalmic","IBI302"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in Best corrected visual acuity ( BCVA ) in the study eye. — At week 44, 48, 52","The proportion of participants with absence intraretinal fluid (IRF) and absence subretinal fluid (SRF) in the fovea at…","Change from baseline in BCVA at Week 52 and 100 — Upto Week 100","Change from baseline in central subfield thickness (CST) measured by optical coherence tomography (OCT) at Week 52 and…","Change from baseline in area of CNV on fundus fluorescence angiography (FFA) at Week 52 and 100 — Upto Week 100","Proportion of participants on a q8W, q12W, and q16W treatment intervals at Week 52 and 100 — Upto Week 100","Incidence, relatedness to the study drug and severity of ocular and Non-ocular adverse events (AE), treatment emergent…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Aflibercept Ophthalmic","IBI302"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05972473","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-09-21 to 2027-04-30","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.878Z","intervention":["Aflibercept Ophthalmic","IBI302"],"participants":600,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in Best corrected visual acuity ( BCVA ) in the study eye. — At week 44, 48, 52","The proportion of participants with absence intraretinal fluid (IRF) and absence subretinal fluid (SRF) in the fovea at…","Change from baseline in BCVA at Week 52 and 100 — Upto Week 100","Change from baseline in central subfield thickness (CST) measured by optical coherence tomography (OCT) at Week 52 and…","Change from baseline in area of CNV on fundus fluorescence angiography (FFA) at Week 52 and 100 — Upto Week 100","Proportion of participants on a q8W, q12W, and q16W treatment intervals at Week 52 and 100 — Upto Week 100","Incidence, relatedness to the study drug and severity of ocular and Non-ocular adverse events (AE), treatment emergent…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41835","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}